SEC Fines Ex-Biotech CEO For Fertility Drug Misstatements

Law360 (June 30, 2020, 9:21 PM EDT) -- A former CEO of a biotech company focused on fertility treatments agreed Tuesday to pay over $119,000 to settle claims from the U.S. Securities and Exchange Commission that she misled investors about the availability and commercial prospects for a product.

Michelle Dipp, a co-founder and ex-CEO of OvaScience Inc., violated federal securities law in 2014 and 2015 by making materially false and misleading statements in SEC filings, press releases, earnings calls and other communications with investors about a treatment that was supposed to enhance in vitro fertilization, the commission said. Dipp — who did not admit to or deny the SEC's...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!